Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: long-time echocardiography follow-up study

Pardos-Gea, José; Avegliano, Gustavo; Evangelista, Arturo; Vilardell, M; Ordi-Ros, José

doi:10.1111/1756-185x.12191

Cited by 28 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A case report from Snipelisky et al shows a patient with antiphospholipid syndrome who had three myocardial infarctions over a period of two weeks, who was treated with primary percutaneous coronary intervention with stent implantation in the fi rst myocardial infarction (5). Th e most frequent nonvalvular cardiac manifestation in patients with antiphospholipid syndrome is pulmonary hypertension (6). According to a follow-up echocardiography study by Kampolis et al in patients with antiphospholipid syndrome and systemic lupus erythematosus, disease duration is an independent factor for the progression of valvular disease, and anticoagulants could not stop the advancement of the valvular dis-FIGURE 2.…”

Section: Discussionmentioning

confidence: 99%

Antiphospholipid syndrome associated with non-infective mitral valve endocarditis: a case report

Stevanović

Mačkić

Džambasović

et al. 2014

JHSCI

View full text Add to dashboard Cite

We present a rare case of antiphospholipid syndrome associated with non-infectious thrombotic endocarditis of the mitral valve. The patient was admitted to hospital for examination because of skin lesions manifested through a discoid skin rash. During the hospitalization antiphospholipid syndrome was diagnosed along with ultrasound verifi cation of vegetations on the mitral valve, including both leafl ets, with moderate to severe mitral regurgitation. Adequate and opportunely introduced therapy led to regression of all symptoms, including endocarditis of the mitral valve on checkup ultrasound verifi cations, with a prevention of arterial and/or venous thrombosis in patient's future.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiphospholipid syndrome associated with non-infective mitral valve endocarditis: a case report

Stevanović

Mačkić

Džambasović

et al. 2014

JHSCI

View full text Add to dashboard Cite

show abstract

“…50 Since then, several authors have confirmed the association of APS and PH; the only exception is a single report by Pardos-Gea et al refuting an increased prevalence of PH in APS. 51 aPL-positive patients might present PH following a PE, might develop PAH associated with systemic sclerosis (SSc), SLE, or other connective tissue disease (CTD), or might present pulmonary venous hypertension associated with Libman-Sacks endocarditis. 48 If PH in the context of APS might be due to several causes, it is undeniable that the most common etiology acknowledges a thrombotic mechanism, as reckoned in 1984 when Anderson and Ali illustrated the case of a 26 year-old male with a positive LA who developed PH following recurrent episodes of DVT and PE despite prolonged anticoagulant therapy.…”

Section: Pulmonary Hypertensionmentioning

confidence: 99%

Lung Disease in Antiphospholipid Syndrome

Maioli

Calabrese

Capsoni

et al. 2019

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is an acquired prothrombotic condition characterized by vascular thrombosis and/or obstetric complications, in the persistent positivity of circulating antiphospholipid antibodies (aPLs). The clinical spectrum of manifestations associated with aPL positivity is progressively expanding, including the description of several lung manifestations. The most common pulmonary involvement related to aPL positivity is pulmonary embolism (PE), which has been reported to occur in 14.1% of APS patients during disease course. PE acknowledges a purely thrombotic etiology and thus might be accounted as a criterion for APS, making imperative to test aPL in young subjects with unprovoked PE. Pulmonary hypertension (PH) can manifest in APS patients, being the second most common lung complication of the syndrome, with a prevalence ranging between 1.8 and 3.5%. aPL-positive patients might present PH following a PE, might develop pulmonary arterial hypertension associated with connective tissue disease, or might present pulmonary venous hypertension due to Libman–Sacks endocarditis. Additional lung manifestations, such as diffuse alveolar hemorrhage, acute respiratory distress syndrome, and pulmonary fibrosis, are rarely described in APS patients; it is still not clear whether in these settings aPLs exert a pathogenic role or is a mere epiphenomenon. Hereby we discuss impact, clinical presentation, histopathologic findings, etiology, and treatment of each aPL-associated lung manifestation.

show abstract

“…In a recent study including 53 patients with primary and secondary (SLE) APS PAH, TTE demonstrated that PAH was the most frequent nonvalve cardiac disease, with a rate of 11.3%. 94 Angio-CT scan is the imaging tool of choice for the evaluation of PE and PE-related PAH in the general population, as in APS as well. 95…”

Section: Pulmonary Arterial Hypertensionmentioning

confidence: 99%

Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies

Tufano

Minno

Guida

et al. 2019

Semin Thromb Hemost

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies, vascular thrombosis (venous, arterial, or small vessels), and/or pregnancy morbidity. Diagnosis of APS is based on the presence of at least one clinical criterion (thrombotic events or pregnancy morbidity) and at least one of the laboratory criteria (persistently medium/high titer immunoglobulin G [IgG]/immunoglobulin M [IgM] anticardiolipin antibodies, and/or medium/high titer IgG/IgM anti-β2-glycoprotein I antibodies, and/or a positive lupus anticoagulant test), confirmed after repetition at least 12 weeks apart. The clinical spectrum of APS encompasses additional (extracriteria) clinical manifestations, including cardiac diseases. Heart involvement may become evident as a consequence of direct (autoimmune-mediated) or indirect (thrombosis) mechanisms, and include valve heart disease (vegetations and/or thickening associated with functional abnormalities) and intracardiac thrombosis, coronary, and vascular accelerated atherosclerosis, along with ischemic heart disease. APS can also cause pulmonary arterial hypertension, left ventricular dysfunction, and heart failure. This review describes the major cardiac manifestations of APS and illustrates the role of cardiac imaging for diagnosing subclinical and overt heart involvement and addressing management of these patients. The possible role of therapeutic strategies in cardiac manifestations of APS is also discussed.

show abstract

Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: long-time echocardiography follow-up study

Abstract: Pulmonary hypertension is the most prevalent non-valvular cardiac manifestation in APS, with an evolution associated with thromboembolic disease, while left myocardial disease and intracardiac thrombi would be rare manifestations in APS.

Cited by 28 publications

References 28 publications

Antiphospholipid syndrome associated with non-infective mitral valve endocarditis: a case report

Antiphospholipid syndrome associated with non-infective mitral valve endocarditis: a case report

Lung Disease in Antiphospholipid Syndrome

Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies

Contact Info

Product

Resources

About